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. Introduction
The identification of small organic ligands
to protein targets is crucial for many ar-
eas of chemical, biological, and pharma-
ceutical research. High-quality organic lig-
ands are fundamental for the discovery of
novel drugs,[ ] of anity-chromatography
supports[ ] and of tool compounds for the
interrogation of biological processes.[ ]
Protein ligands can often be discov-
ered using conventional high-throughput
screening (HTS) of compound collections,
but these procedures can be expensive,[ ] require complex lo-
gistics and are typically limited to the analysis of a few hun-
dred thousand compounds.[ ] The encoding of chemical com-
poundswithDNA fragments serving as amplifiable identification
barcodes, first postulated by Brenner and Lerner,[ ] is growing
in popularity as a ligand discovery methodology, both in indus-
try and in academia. DNA-encoded chemical libraries (DELs) do
not require dedicated logistics for the handling of library mem-
bers, since the DNA tag allows the facile identification of binding
molecules by PCR amplification and DNA sequencing.[ ]
In most cases, DELs are interrogated by anity-capture on tar-
get proteins of interest, immobilized on a solid support,[ ] but al-
ternative methodologies (e.g., those based on photocrosslinking,
on capillary electrophoresis or on interaction-dependent PCR
procedures) have been proposed.[ ]
In principle, highly complex DELs can be constructed by the
iterative assembly of multiple sets of building blocks. [b, ] How-
ever, the incorporation of three or more chemical moieties may
result in molecular structures that violate Lipinski’s rules of five
and which may be too large for pharmaceutical applications.[ ]
In some cases, DEL-derived binders comprising multiple build-
ing blocks may be reduced in size by retaining only those struc-
tural elements that contribute most of the binding energy.[ ] Al-
ternatively, DELs can be constructed using two sets of building
blocks, yielding “hits” which can be subsequently optimized by
medicinal chemistry.[a,a, ]
Here, we describe the construction of a novel versatile DEL
based on two sets of building blocks, coupled to a central stereo-
defined -azido--methoxy--oxopentanoic acid. The GB-DEL li-
brary, whose members were typically smaller than  Da, was

























































Figure . Schematic representation of the synthetical steps involved in GB-DEL formation. The two sets of building blocks, A and B, and the correspond-
ing encoding DNA portions are color-coded in red and blue, respectively. The first set of building blocks A was conjugated to DNA via reverse amide
bond. The building blocks B were linked to the library either by amide bond formation or CuAAC click reaction. a) Amide bond formation of three hundred
dierent oligonucleotides (described as CodeA) with  (EDC/S-NHS, DIPEA, r.t. ’, in TEA buer  × − , pH = ,  °C); b) deprotection of
scaold’s methyl ester (LiOH  × − ); c) reverse amide bond formation (On-DNA-COOH,  × −  DMTMM in MOPS  × − ,  
NaCl, pH = ) of each of the three hundred dierent scaold-oligo conjugates with an amine (building blocks A). Each of the CodeA-building block A
conjugates was individually purified by HPLC and pooled in equimolar amount to form pool step . The pool step  was split in  wells. d) Wells –
underwent Staudinger reduction (× −  TCEP in × −  TRIS, pH = .), e) coupling to a carboxylic acid and f) encoding with CodeB –
by splint ligation (Ligase buer, NEB T-DNA ligase (f )); g) CuAAC click reaction (× −  Borate buer, pH= .,  × −  CuSO mqHO,  ×
−  sodium ascorbate in HO) of N -pool step  (wells –) with alkynes ( ×
− ) and subsequent splint ligation (f )). After pooling and
purification by RP-HPLC, the single stranded DEL was used directly in single pharmacophore selections or paired to a complementary oligonucleotide
displaying a known protein binding moiety “HIT” to perform   dual pharmacophore anity maturation selections.+
screened against multiple targets, allowing the discovery of novel
binders whichwere compatible with Lipinksi’s rule of five. While
mostDELs described so far had featured DNA in double-stranded
format,[b, ] we used single-stranded DNA barcodes in order
to enable modular lead expansion procedures by DNA self-
assembly. The results of this article illustrate how novel protein
ligands can eciently be discovered in single-stranded format
and how ligands can be conveniently assembled with a single-
stranded DEL yielding dual-display anity maturation libraries.
This approach may practically be used in iterative assembly and




The first step for the synthesis of our library (termed GB-
DEL) was performed by coupling the -azido--methoxy--
oxopentanoic acid () onto  distinct amino-tagged oligonu-
cleotides (Figure ).
We used a : mixture of the R and S stereoisomers, with the
aim to assess the contribution of chirality to protein recognition
at the hit validation stage. The glutamic acid derivatives were de-
protected and allowed to react with  amines ( primary, 
secondary and  (hetero) aromatic amines), plus one code re-
served for ammonia, serving as a control (“building blocks A”).
The resulting conjugates were individually HPLC-purified, prior
to pooling and splitting for the second coupling step with “build-
ing blocks B”. At this stage, we converted  aliquots of the
mixture (each containing the  building block A conjugates)
into the corresponding primary amines which were later reacted
with  carboxylic acids. In parallel,  aliquots of -azido glu-
tamic acid derivatives were reacted with terminal alkynes us-
ing copper(I)-catalyzed alkyne azide cycloaddition (CuAAC), us-
ing a previously optimized procedure.[ ] The second reactions
step was encoded by splint ligation[c] with  oligonucleotides,
yielding a library comprising  (stereoisomers) x  (building

























































blockA derivatives) x  (building block B derivatives)  =
compounds (Figure  and Figures S–S, Supporting Informa-
tion). Compounds were eventually pooled and HPLC-purified.
GB-DEL in single-stranded DNA format could be used as such
for protein selections (Streptavidin, CAIX, FAN, AASS, PIK),
or hybridized to complementary oligonucleotide derivatives bear-
ing a protein-binding moiety for anity maturation procedures
(CREBBP, HSA, CAIX, tyrosinase, and trypsin) (Figures S–
S, Supporting Information). Specific binders with dissociation
constant in the single-digit micromolar or in the submicromolar
range were isolated, as illustrated in the following sections.
.. Selection Experiments against Protein Targets using the
Library in Single-Stranded DNA Format
... DEL Selections against Streptavidin and CAIX
Library aliquots containing  copies of each compound were
used for direct library selection. In total, more than   such
aliquots were available. Anity capture experiments with pro-
teins immobilized on magnetic beads were typically performed
in triplicate, using previously described procedures.[a] For clar-
ity sake, only one fingerprint is shown in the main body of
the article, but replicate selection results can be found in Fig-
ures S–S (Supporting Information). We characterized the
unselected library by high-throughput DNA sequencing and ob-
served a uniform distribution of sequence counts for the vari-
ous librarymembers, thus providing confidence about the proper
execution of the various mixing steps during library synthesis
( a). The majority of library compounds had molecularFigure 
weights < Da (Figure d) and were compliant with Lipinski’s
rule of five (Tables S and S, Supporting Information). [, ]
Since most selections were performed using biotinylated pro-
tein targets, we conducted selections on “empty” streptavidin-
coated magnetic beads. Only one slightly enriched compound
was found which was structurally reminiscent of the high an-
ity streptavidin binder biotin (Figure e, compounds , ). The
compounds displayed a weak interaction with streptavidin, with
dissociation constants Kd =  ±  and  ± × − , re-
spectively, which were measured by a small molecule ELISA
procedure, recently described by our group.[ ] Selections were
also performed against human carbonic anhydrase IX, a tumor-
associated antigen and a marker of hypoxia.[ ] As expected, aro-
matic sulfonamides derivatives were found to be preferentially
enriched (with enrichment factors (EF) up to -fold), as re-
vealed by the lines at coordinates A, A, and B of the
fingerprints in D display mode (Figure c). For all subsequent
selections, screening results were displayed in the more compact
pseudo-D representation.[ ]
... DEL Selections against FAN, AASS, and PIK
We performed selections against proteins of pharmaceutical
interest ( ). FANCD-associated nuclease  (FAN) isFigure 
DNA repair nuclease implicated in the resolution of inter-strand
crosslinks (ICLs) and in protective responses at stalled replica-
tion forks.[ ] Moreover, it has been reported that FAN is crit-
ical to maintain genome integrity in BRCA-deficient cells.[ ]
Therefore, small-molecule FAN inhibitors may also represent
a promising strategy for treatment of BRCA-mutated carriers.
Based on the canSAR cancer drug discovery platform and using
the chemical properties and bioactivity of small molecules anno-
tated in ChEMBL database, it has been estimated that FAN is
among DNA damage response (DDR) factors predicted to be
druggable.[ ]
Selections were performed both on His-tagged wild-type
FAN and on a nuclease-dead variant (DA) carrying a muta-
tion in themetal-coordinating active site (Figure Sa,b, Support-
ing Information).[ ] A preferential enrichment of two lines, cor-
responding to building blocks B and B (two regioisomers
of catechol derivatives) was observed (Figure a,b). The building
block combination (A/B) inspired the synthesis of the two
stereoisomers  and , which, however, bound to both versions
of FAN with comparable anities (Kd . . = ± × − ;
Figure c), most likely to a remote epitope, as they do not in-
hibit FAN enzymatic activity. Indeed, partial inhibition of FAN
’Flap endonuclease activity by A/B was seen only in the
 × −  range (Figure S,c, Supporting Information).
Human alpha-aminoadipic semialdehyde synthase (AASS)
catalyzes the first two steps of lysine catabolism. Inhibition of
AASS is proposed as a substrate reduction therapy[ ] for an auto-
somal recessive neonatal seizure disorder, pyridoxine-dependent
epilepsy (PDE), caused by mutations in the ALDHA gene en-
coding the enzyme downstream of AASS.[ ] Selection experi-
ments against the saccharopine dehydrogenase domain of AASS
revealed a preferential enrichment of the A/B building
block pairs (Figure d). Conversion of this chemical information
into the stereoisomeric compounds  and  resulted in an ap-
parent dissociation constant in the submicromolar concentration
range (Kd = . . ± × −  for compound ) (Figure e).
The p/p dimeric [ ] isoform of PIK (phosphatidyli-
nositol -kinase) was the target of selections described in (Fig-
ure f). The regulatory subunit p combines with the catalytic
subunits p to form the PIK complex. Three struc-/P
turally related pairs of building blocks (A/B, A/B,
and A/B), with nitrogen-containing heterocycles, were
among themost enriched features in thefingerprints (Figure g).
Binding assays performed with compounds – revealed a
strong influence of the stereocenter on the binding anity for
the A/B combination ( -fold dierence between R and S
stereoisomers). A lower impact of the stereocenter was observed
for A/B and no dierence in binding anity was seen for
the two A/B enantiomers (Figure g).
.. Library Expansion by   Self-Assembly with+
Complementary Oligonucleotide Derivatives
The single-stranded DNA format of the GB-DEL allowed the
facile annealing with chemically modified complementary DNA
strands, carrying a protein-binding moiety (“hit”) at the ’ end.
This feature allowed us to compare selections performedwith the
unmodified GB-DEL and with the self-assembly products, fea-
turing three sets of building blocks ( a). We paired theFigure 
GB-DEL with a complementary DNA strand, carrying hits of in-
termediate anity, in order to discover combinations of building
blocks which could enable an anity maturation procedure, us-
ing multiple proteins as targets.

























































Figure . a) (left) High-throughput DNA sequencing (HTDS) plot of unselected library GB-DEL. The , ,x y z axes of the tridimensional plot represent
CodeA/CodeB and sequence counts of the GB-DEL. Total sequence counts (TCs) =   , average sequence counts (ACs) = . b) HTDS plot
of streptavidin selections (TCs = ’, ACs = .). The arrow indicates the most enriched CodeA/CodeB combination (A/B) which was re-
synthetized o-DNA (right panel compounds , ). c)HTDS plot of CAIX selections. TCs=  , ACs= .. (Right) Aromatic sulfonamide derivatives
were included in the library as positive controls: A, A, and B. Indicated by the arrows are the two most enriched building block combinations,
A/B and A/B, whose molecular structures and enrichment factors can be found in Table S (Supporting Information). d) Histogram of GB-
DEL final molecules’ molecular weights distribution. On the x axis molecular weights for the CodeA/CodeB combinations, on the axis molecular weighty
frequency. The mean of the Gaussian distribution corresponds to MW . g mol−. e) Enzyme-linked immunosorbent assay (ELISA) of compound
,  against streptavidin. The measurements have been performed in triplicate ( ). The Kd valuesn = ± ±standard error for compound  and  are 
 and  ± × − , respectively.


















































































































CREBBP is a bromodomain-containing transcriptional co-
regulator, which regulates a number [ ]of key intracellular
processes.[ ] CREBBP selections featured a benzodiazepinone
(HIT) on the complementary DNA strand. This chemical moi-
ety had previously been described as a  × −  binder.[ ]
A preferential enrichment of the synergistic building blocks
A/Bwas observed in the selection with three sets of build-
ing blocks (“dual-pharmacophore library”), while a substantially
lower enrichment was seen using the unmodified GB-DEL li-
brary (“single-pharmacophore library”) (Figure b). Anity mea-
surements performed by fluorescence polarization with DNA-
LNA hybrids [c, ] revealed a binding increase for the triple com-
bination of building blocks, while the A/Bmoiety had an
undetectable interaction with the protein at concentrations be-
low  × − . Similarfindings have recently been reported for
other dual-pharmacophore systems. [c,,]
HSA, human serum albumin, is the most abundant protein
in serum which has been used as target for pharmacokinetic
modulation strategies. [ ] For HSA selections, the GB-DEL was
paired with a -(p-iodophenyl)butanoic acid moiety (HIT) that
we had previously described as a portable HSA binder. [d] A
striking potentiation of the A/B was observed, while the
A/B combination had similar enrichments in both single-
and dual-pharmacophore format (Figure c). Similar findings
were observed for anity-maturation selections against other
protein targets, including the tumor-associated antigens CAIX
and tyrosinase [,] (Figure S, Supporting Information). In or-
der to confirm that the binding potentiation seen “on DNA” could
be translated into small organic ligands devoid of any DNA com-
ponent, we resynthesized the A/B/HIT and A/B
HSA hits as small organic molecules – (Figure ). The best
binding combination from the “on DNA” experiments of Fig-
ure c also gave the best binding results “o DNA,” with an ap-
parent dissociation constant Kd for compound  of  ± × −
 (Figure d).
. Conclusion
We have synthesized a novel DNA-encoded chemical library (GB-
DEL), using a glutamic acid derivative as scaold for the simulta-
neous display of two sets of building blocks. The librarywas used
to isolate and characterize small molecule ligands against multi-
ple target proteins. The strategic choice to encode the GB-DEL
with DNA in single-stranded format opens the possibility to per-
form selection schemes based on photo-crosslinking (e.g., by hy-
bridization with oligonucleotide-photosensitizer conjugates[a,]
and to implement anity-maturation with oligonucleotide-hit
conjugates (Figure ). Some of the hit compounds isolated from
theGB-DELmay be useful in practice andmay deserve additional
medicinal chemistry optimization.
We have discovered two novel binders of FAN, a versatile
DNA nuclease involved in ICL repair and replication stress re-
sponse. The two molecules (compounds  and ) bound with
high anity (Kd in the  × −  range) to both wt and
nuclease-dead FAN variants (amino acids –) and exhib-
ited only poor endonuclease inhibitory activity, suggesting that
the binding site might map to a dierent portion of the pro-
tein. Besides the C-terminal nuclease domain, other structural
regions of the FAN fragment used in the selections include
the SAP (SAF-A/B, Acinus and PIAS) motif and the TPR (tetra-
tricopeptide repeat) module responsible for homo-dimerization
and DNA-binding.
We have also isolated ligands  and  which bound tightly
to AASS (alpha-aminoadipic semialdehyde synthase), an en-
zyme involved in the major lysine degradation pathway[ ] im-
plicated as therapy for pyridoxine-dependent epilepsy (PDE). The
pathogenic driver of PDE is the accumulation of −aminoadipate
semialdehyde (AASA; a substrate for ALDHA)[ ] and of its
cyclic form L- -piperidine- carboxylate (PC). PC reacts with
pyridoxal ’-phosphate and reduces the availability of this essen-
tial cofactor for normal cellular functions.[ ] The inhibition of
AASS, upstream of the ALDHA pathway, may allow to reduce
AASA/PC levels and thus serve as substrate reduction therapy
for the treatment of PDE.[b]
PIK selections have revealed an intriguing contribution of the
library scaold’s chirality for protein recognition, with a ten-fold
improved anity for compound  over its stereoisomer . The
protein target is a member of the lipid kinases family, which reg-
ulates signaling pathways important for cell proliferation, adhe-
sion, survival, and motility.[ ] The PIKCA gene, coding for the
p subunit, is frequently mutated in cancer [ ] and repre-
sents an attractive target for the development of small molecule
inhibitors, some of which are currently in preclinical evaluation
and some are approved therapeutics.[ ]
The GB-DEL features DNA in single-stranded DNA format,
which may facilitate its hybridization with chemically modified
complementary oligonucleotides. This feature may be useful for
a number of applications, including the execution of DEL se-
lections with photocrosslinkers. [a] Small ligands isolated from
DELs often display suboptimal kinetic dissociation constants and
may be lost during washing procedures in the screening experi-
ments. The display of a photocrosslinker on the complementary
strandmay help stabilize complex formation and facilitate the re-
covery of preferential binders.[c,]
The stable non-covalent assembly of complementary DNA
structures also facilitates the lead expansion of hit com-
pounds. Our group had previously described the use of encoded
Figure . High-throughput DNA sequencing plots of a) wt FAN (TCs .); b) DA FAN (TCs .); d) AASS=  , ACs = =  , ACs =
(TCs=  , ACs .) and f) PIK (TCs  , ACs= = = .). The plane of the bidimensional plots represent Code A and Code B, respectively.x y,
The jet scale and the dots color code indicate code sequence counts. The arrows indicate Code A/Code B combinations selected for re-synthesis (com-
pounds –), the colors, red and blue, indicate building block A and B, respectively. c,e,g) ELISA binding assays of compounds against their protein
targets. c) Compounds – against wt and DA FAN; e) compounds – against AASS; g) compounds – against PIK; on the axis concentrationx
(), on the stereoisomer, respectively. Kd measurements have been performed iny axis absorbance at  nm. Red and blue curves indicate R and S
triplicate (n = ). Error bars on the curve indicate standard deviation of the three measurements. The Kd values ± standard error for compound –
are given next to the chemical structures. Structures of CodeA/CodeB combinations selectively enriched in the FAN selection (A/B, A/B,
and A/B) can be found in Table S (Supporting Information).


















































































































self-assembling chemical (ESAC) libraries as an avenue for the
discovery of synergistic pairs of building blocks that may inter-
act with the cognate target in a bidentate fashion and provide an
anity gain through the “chelate eect”.[c,] The anity mat-
uration strategy described in this article represents an extension
of the ESAC strategy, leading to the identification of three chem-
ical moieties which may synergistically interact with the target
protein of choice. The procedure was exemplified for the anity
maturation of ligands for the CREBBP bromodomain and HSA.
Compound re-synthesis in the absence of DNA, combined with
a judicious linker optimization, may lead to an additional gain in
binding anity (e.g., Kd =  ± × −  for the HSA binder).
Indeed, the molecular features of the linker may positively or
negatively aect the anity constant of the resulting bidentate
ligand. [ ]
In spite of its relatively small size (  compounds), the
GB-DEL generated hits against multiple target proteins of phar-
maceutical interest. The glutamic acid scaold provided a direc-
tional display of functional group pairs which could synergisti-
cally interact with the cognate protein. The reactions used for
library synthesis proceeded with excellent conversion yields,[a]
contributing to the overall quality and reproducibility of screen-
ing experiments which were conducted in triplicate. The single-
stranded DNA format used for library encoding is likely to find a
broader applicability in the future, not only because of its versa-
tility but also because it often yields better selection results com-
pared to the double-stranded DNA format in terms of ligand re-
covery and signal-to-noise ratios.[ ]
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